You just read:

Hoth Therapeutics Announces Positive Preclinical Data of WEG232 Treatment, Developed for Cancer Patients Suffering from Erlotinib-Induced Facial Dermatitis and Hair Loss

News provided by

Hoth Therapeutics, Inc.

Mar 19, 2020, 10:05 ET